Targeting B lymphocytes in progressive fibrosing mediastinitis

American Journal of Respiratory and Critical Care Medicine

Volumn 190, Issue 9, 2014, Pages 1069-1071

  Westerly, Blair D ^a   Johnson, Geoffrey B ^a   Maldonado, Fabien ^a   Utz, James P ^a   Specks, Ulrich ^a   Peikert, Tobias ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; FLUORODEOXYGLUCOSE F 18; ITRACONAZOLE; PREDNISONE; RITUXIMAB; MONOCLONAL ANTIBODY;

ADULT; B LYMPHOCYTE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEMOGRAPHY; FEMALE; FIBROSING ALVEOLITIS; HISTOPLASMOSIS; HUMAN; INFORMED CONSENT; LETTER; LYMPHOCYTIC INFILTRATION; MALE; MEDIASTINITIS; MIDDLE AGED; PET-CT SCANNER; PRIORITY JOURNAL; PROGRESSIVE FIBROSING MEDIASTINITIS; SCLERODERMA; TREATMENT RESPONSE; TUMOR VOLUME; DISEASE COURSE; DRUG EFFECTS; SCLEROSIS;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MEDIASTINITIS; MIDDLE AGED; SCLEROSIS;

EID: 84922393436     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201407-1258LE     Document Type: Letter

References (17)

1. Goodwin RA, Nickell JA, Des Prez RM. Mediastinal fibrosis complicating healed primary histoplasmosis and tuberculosis. Medicine (Baltimore) 1972;51:227-246.
2. Davis AM, Pierson RN, Loyd JE. Mediastinal fibrosis. Semin Respir Infect 2001;16:119-130.
3. Peikert T, Colby TV, Midthun DE, Pairolero PC, Edell ES, Schroeder DR, Specks U. Fibrosing mediastinitis: clinical presentation, therapeutic outcomes, and adaptive immune response. Medicine (Baltimore) 2011;90:412-423.
4. Loyd JE, Tillman BF, Atkinson JB, Des Prez RM. Mediastinal fibrosis complicating histoplasmosis. Medicine (Baltimore) 1988;67:295-310.
5. Urschel HC Jr, Razzuk MA, Netto GJ, Disiere J, Chung SY. Sclerosing mediastinitis: improved management with histoplasmosis titer and ketoconazole. Ann Thorac Surg 1990;50:215-221.
6. Savelli BA, Parshley M, Morganroth ML. Successful treatment of sclerosing cervicitis and fibrosing mediastinitis with tamoxifen. Chest 1997;111:1137-1140.
7. Dines DE, Payne WS, Bernatz PE, Pairolero PC. Mediastinal granuloma and fibrosing mediastinitis. Chest 1979;75:320-324.
8. Doyle TP, Loyd JE, Robbins IM. Percutaneous pulmonary artery and vein stenting: a novel treatment for mediastinal fibrosis. Am J Respir Crit Care Med 2001;164:657-660.
9. Garrett HE Jr, Roper CL. Surgical intervention in histoplasmosis. Ann Thorac Surg 1986;42:711-722.
10. Albers EL, Pugh ME, Hill KD, Wang L, Loyd JE, Doyle TP. Percutaneous vascular stent implantation as treatment for central vascular obstruction due to fibrosing mediastinitis. Circulation 2011;123:1391-1399.
11. François A, Chatelus E, Wachsmann D, Sibilia J, Bahram S, Alsaleh G, Gottenberg JE. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res Ther 2013;15:R168.
12. Xue J, Kass DJ, Bon J, Vuga L, Tan J, Csizmadia E, Otterbein L, Soejima M, Levesque MC, Gibson KF, et al. Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients. J Immunol 2013;191:2089-2095.
13. Atkins SR, Turesson C, Myers JL, Tazelaar HD, Ryu JH, Matteson EL, Bongartz T. Morphologic and quantitative assessment of CD201 B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum 2006;54:635-641.
14. Komura K, Yanaba K, Horikawa M, Ogawa F, Fujimoto M, Tedder TF, Sato S. CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. Arthritis Rheum 2008;58:3574-3584.
15. Matteson E, Bongartz T, Ryu JH, Crowson CS, Hartman TE, Dellaripa PF. Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Open J Rheumatol Automimmune Dis 2012;3:53-58.
16. Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O; on behalf of the EUSTAR Rituximab study group. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2014.
17. Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, Nicholson AG, Hansell DM, Wells AU, Renzoni EA. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 2014;19:353-359.